Clinical Brief
Immunologic Suppression by Methotrexate in Dermatology
Abstract
Warnings have been issued by both the FDA and the manufacturer that methotrexate, an antimetabolite, is a hazardous drug only to be used under the most stringent surveillance. This study points up a potential danger in the use of the drug.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
